AXIN1 and hepatocellular carcinoma: Aberrant WNT/β-catenin signaling has been detected in up to 66% of HCC cases (mutually exclusive mutations in CTNNB1, AXIN1, and APC, and CCND1-FGF19 amplification) [7].